Market Capitalization (Millions $) |
175 |
Shares
Outstanding (Millions) |
27 |
Employees |
- |
Revenues (TTM) (Millions $) |
6 |
Net Income (TTM) (Millions $) |
-77 |
Cash Flow (TTM) (Millions $) |
13 |
Capital Exp. (TTM) (Millions $) |
1 |
Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing gene and cell therapies for rare and life-threatening genetic diseases. The company is dedicated to transforming the lives of patients suffering from rare genetic diseases by developing innovative treatments that address the underlying cause of the disease.
Abeona Therapeutics has a diverse pipeline of potential therapies, with a particular focus on treating patients with rare genetic conditions such as Sanfilippo syndrome, Batten disease, and epidermolysis bullosa. The company's therapies aim to either replace missing or malfunctioning genes or to modify the patient's own cells to produce the missing proteins.
The company is committed to conducting thorough research and running clinical trials to ensure the safety and efficacy of their therapies. In addition to developing new treatments, Abeona Therapeutics also collaborates with academic institutions and other companies to improve and expand the field of gene and cell therapies.
Overall, Abeona Therapeutics Inc. is a pioneering biopharmaceutical company that strives to develop revolutionary therapies for rare genetic diseases, providing hope to patients and their families.
Company Address: 6555 Carnegie Avenue Cleveland 44103 OH
Company Phone Number: 813-4701 Stock Exchange / Ticker: NASDAQ ABEO
|